Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $2.8 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.8 million, down 8.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 8.22% YoY), and the FY2025 annual result was $2.8 million, down 8.06% from the prior year.
• Other Non-Current Liabilities came in at $2.8 million for Q1 2026 at Prelude Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.4 million in Q4 2022 to a low of $2.4 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $3.2 million (2024), against an average of $3.1 million.
• Across the five-year window, Other Non-Current Liabilities jumped 40.04% in 2023 and slipped 8.22% in 2026, its largest moves.
• Prelude Therapeutics' Other Non-Current Liabilities stood at $3.4 million in 2022, then slipped by 0.65% to $3.3 million in 2023, then slipped by 7.46% to $3.1 million in 2024, then retreated by 8.06% to $2.8 million in 2025, then retreated by 2.18% to $2.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.